Showing results (1-10 of 399) with videos related to
Sort By:
Pageof 40
Circulation|July 6, 2026
Cardiovascular Risk Reduction With GLP-1 RA DrugsMarie Pigeyre, Hertzel C GersteinCardiovascular Diabetology|September 3, 2024
Relationships between ankle blood pressure indices and major adverse cardiovascular events in people with and without type 2 diabetesKamel Mohammedi, Marie Pigeyre, Jackie Bosch, et al.European Heart Journal|March 1, 2024
Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort studyKamel Mohammedi, Marie Pigeyre, Jackie Bosch, et al.Elife|October 16, 2020
Effects of lifelong testosterone exposure on health and disease using Mendelian randomizationPedrum Mohammadi-Shemirani, Michael Chong, Marie Pigeyre, et al.American Journal of Human Genetics|February 16, 2020
Influence of Genetic Ancestry on Human Serum ProteomeJennifer Sjaarda, Hertzel C Gerstein, Zoltan Kutalik, et al.Diabetes, Obesity & Metabolism|May 15, 2024
Determinants of serious health outcome-free status in middle-aged and older people with dysglycaemia: Exploratory analysis of the ORIGIN trialKamel Mohammedi, Sibylle Hess, Matthew McQueen, et al.Diabetes/Metabolism Research and Reviews|September 27, 2002
Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPEHertzel C GersteinEndocrinology and Metabolism Clinics of North America|September 14, 2002
Epidemiologic analyses of risk factors, risk indicators, risk markers, and causal factors. The example of albuminuria and the risk of cardiovascular disease in diabetesHertzel C GersteinNature Reviews. Endocrinology|May 16, 2009
Is it possible to reduce cardiovascular risk with glucose-lowering approaches?Hertzel C GersteinEndocrinology and Metabolism Clinics of North America|March 9, 2005
Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?Hertzel C Gerstein, Julio RosenstockPageof 40